Working Backwards with the Benefit of Hindsight, Does not Render Compound Obvious
In Amerigen Pharmaceuticals Limited v. UCB Pharma GmbH, [2017-2596] (January 11, 2019), the Federal Circuit claims affirmed the PTAB’s determination that claims 1–5 and 21–24 of U.S. Patent 6,858,650 on an antimuscarinic drug marketed as Toviaz® to treat urinary incontinence … Continue reading Working Backwards with the Benefit of Hindsight, Does not Render Compound Obvious
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed